NAS:NDRA (USA)
ENDRA Life Sciences Inc $ 2.22 0.09 (4.23%)
Volume:
2,369,125
Avg Vol (1m):
4,067,570
Market Cap $:
83.44 Mil
Enterprise Value $:
80.35 Mil
PE Ratio:
0.00
PB Ratio:
15.84
Financial Strength | 5/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Cash-To-Debt | 5.4 | ||
Debt-to-Equity | 0.21 | ||
Debt-to-EBITDA | -0.06 | ||
Piotroski F-Score | 3 | ||
Altman Z-Score | 0 | ||
Beneish M-Score | 0 | ||
WACC vs ROIC |
Profitability Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
ROE % | -727.03 | ||
ROA % | -305.03 | ||
ROC (Joel Greenblatt) % | -1799.54 | ||
3-Year Revenue Growth Rate | -100 | ||
3-Year EBITDA Growth Rate | -48.4 | ||
3-Year EPS without NRI Growth Rate | -48.8 |
NDRA
Valuation Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
PB Ratio | 15.84 | ||
EV-to-EBIT | -6.48 | ||
EV-to-EBITDA | -6.55 | ||
Current Ratio | 3.42 | ||
Quick Ratio | 3.19 |
Dividend & Buy Back |
Current | Vs Industry | Vs History | |
---|---|---|---|
3-Year Average Share Buyback Ratio | -29.2 |
Valuation & Return |
Current | Vs Industry | Vs History | |
---|---|---|---|
Price-to-Tangible-Book | 15.86 | ||
Earnings Yield (Greenblatt) % | -15.45 |